





S-figure 1 Structures of (A) teixobactin and (B) arg10 teixobactin with the residues numbered 1-11, D amino acids highlighted 
in red and the structural differences marked in blue. (C) Structure of moenomycin A showing its polar (cyan) and 
hydrophobic (magenta) regions. 
 
S-table 1 Primers sequences used to amplify a staphylococcal specific region of the 16S rRNA gene, and the mecA gene that 
conveys methiciliin resistance. 








S-1 The effect of moenomycin A and arg10-teixobactin evolved resistance on 
growth rate of S. aureus 
 
S-figure 2 The average growth of ancestral, evolved moenomycin A, evolved arg10-teixobactin and evolved rifampicin 
resistant strains under stresses as an indicator for fitness. The average absorbance at 620nm for each strain generated 
compared with the starting ancestor strain across a range of conditions at 37°C unless otherwise stated. From top left 
clockwise: (A) Unaltered MH, (B) MH supplemented with moenomycin A to 10% MIC, (C) MH supplemented with rifampicin 
to 10% MIC, (D) MH supplemented to 150µM EDTA, (E) MH supplemented to 10% NaCl, (F) MH media at 44
o
C and (G) MH 







S-figure 3 The mean maximal population growth of ancestral, evolved moenomycin A, evolved arg10-teixobactin and 
evolved rifampicin resistant strains under stress conditions after 20 hours, used as an indicator of fitness. The average 
absorbance at 620nm for each strain generated compared with the starting ancestor strain across a range of conditions at 
37°C unless otherwise stated.   N=3, where visible error bars represent SEM. 
 
 
S-table 2 The mean rates of intrinsic increase (r) per unit of time or growth rates derived from changes in optical density of 
moenomycin A, arg10- teixobactin and rifampicin resistant strains and selection free cells relative to the ancestral strain 
(rate of 1) across a range of sub-lethal stress conditions in a base Mueller Hinton media. * indicates significant difference 





















0.996 N/A 0.122* 1.361* 0.722* 0.941 1.216* 
Moenomycin  A 
(45days 
selection) 
0.952 0.773* 3.068* N/A 0.783* 1.267* 1.124* 
Rifampicin (45 
days selection) 
0.739* 0.643* 6.881* 0.616* 0.417* 0.473* 1.095 
Control (45 days 
without selection) 
0.763* 1.095* 0.706 1.049 0.551* 1.072 1.093 
 
S-2.1 Discussion of induced resistance mechanisms 
The role and location of common mutations found within moenomycin A resistant 
strains  
Mutations unique to moenomycin A resistant were observed across three key genes, these were 
acquired across all six replicate strains. Two of these genes, penicillin-binding protein 2 (pbp2) and a 
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bifunctional autolysin (SagB), play key roles in cell wall modulation, whilst purR is the regulatory 
domain of cellular Purine metabolism (1).  
Pbp2, an important component of cell wall synthesis, is a bifunctional enzyme which catalyses the 
formation of the NAG-NAM β-1-4 carbohydrate and amide linkages within peptidoglycan. 
Moenomycin A is a well know inhibitor of pbp2, preventing the formation of the nascent 
peptidoglycan chain. Multiple mutations were observed in the active site of pbp2. This is consistent 
with Rebets et al who previously described individual active site mutations in two of these positions 
(Y196 and P234) individually these gave rise to a 25-fold increase in resistance. SagB is a bifunctional 
autolysin which modulates mature peptidoglycan and has a role in cell wall restructuring. SagB is a 
family 73 muramidase, which cleaves the NAG NAM β-1-4 peptidoglycan linkage. The F134L mutation 
appears to be away from the SagB activate site. purR is the repressor protein regulating the purine 
biosynthetic pathway. The I154* mutation causes a truncation of purR resulting in the loss of the 5-
phospho ribosyl 1-pyrophosphate binding site. This may constitutively induce transcription of the Pur 
operon. Purine biosynthesis is linked to DNA and ATP metabolism, and its upregulation may play a 
role in offsetting the cost of resistance. The effect of all mutations working in concert gave rise to 
~1000-fold increase in moenomycin resistance across all six strains. 
 
The role and location of common mutations found within arg10-teixobactin resistant strains  
Strains with resistance against arg10-teixobactin showed three distinct paths to resistance. Though 
there was little overlap between these mechanisms, there are common themes of modifications with 
links to lipid biosynthesis, cell wall modifications and energy metabolism. 
Path one: four arg10-teixobactin resistant strains carried identical mutations in Phosphatidylglycerol 
lysyltransferase (mprF), transcriptional regulatory protein (srrA), KDP operon transcriptional 
regulatory protein (kdpE) and DNA gyrase subunit A (gyrA). The tolerance of these strains was: Strain 
1 (8µg/mL), strain 2 (8µg/mL), strain 3 (4µg/mL) and strain 4 (5.3µg/mL). mprF has been previously 
implicated in modifying staphylococcal lysylphosphatidylglycerol to convey a net extracellular 
positive charge, reducing susceptibility to several cationic antimicrobial peptides(2) . srrA and kdpE 
are phospho-relay signal transduction proteins which regulate separate, two-component signalling 
pathways. These influence a number of downstream processes thought to be immunomodulatory 
and virulence linked (14, 15). gyrA is subunit of DNA gyrase which is responsible for negatively 
supercoiling DNA(3).  Two further mutations appear to increase resistance further, the glutamine 
methyltransferase (PRM C) present in strains 1, 2 & 4 and protein dltD (dltD) present in strains 1 & 2.  
prmC regulates gene expression through methylation of the ‘GGQ motif’ and is crucial to bacterial 
protein translation (4). DltD involved in D-alanylation of lipoteichoic acid and potentially influencing 
the charge of the cell wall excluding charged compounds from their active sites (5). 
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Path two: Strain 6 exhibited the joint highest tolerance to arg10-teixobactin (8µg/mL), harbouring 
three primary mutation, the putative peptidoglycan glycosyltransferase FtsW (ftsW), Extracellular 
matrix-binding protein (ebh1) and Isocitrate dehydrogenase (icd).   
FtsW is one of a number of proteins suggested to function as a lipid II flippase and peptidoglycan 
synthase (6, 7), like pbp2 it has been speculated to catalyse the incorporation of lipid II into 
peptidoglycan, though unproven, this may identify a mechanism requiring further study. Lipid II has 
been shown to be the primary target for teixobactin (figure 3 panel a). Ebh1, is a > 400 Kda protein, 
thought to sequester harmful compounds including antimicrobial peptides (8). Isocitrate 
dehydrogenase (Icd) is an enzyme found within the TCA cycle. An A317P point mutation was 
observed within ICD. This near active site mutation may lead to a shift in cellular energy metabolism.  
Path three: arg10-teixobactin resistant strain 5 acquired moderate resistance (5.3 µg ml
-1).  Mutations 
were found within a Tyrosine-protein kinase (YWQ D) and Protoporphyrinogen oxidase (hemY). YwqD 
is a close homologue of a regulatory protein for the capsule biogenesis pathway (9). An increase in 
extracellular capsid production has been previously implicated in intermediary vancomycin 
resistance, this may carry over into resistance to other cell wall targeting antimicrobials (22).  HemY 
is a Protoporphyrinogen oxidase which catalyses the oxidation of haem precursors (10).  An M1V 
mutation resulted in the loss of start codon and subsequent truncation of the protein.  
In addition to these identified adaptations, several mutations were identified in two genes with 
commonality between all 12 sequenced strains. These two genes appear to be immediately next to 
one another in an ORF encoding hypothetical proteins of no certain function. Such proximity and 
commonality in mutations suggests these sites are either important adaptations under the 
experimental conditions, or that they are sites key to the evolution of resistance to these antibiotics 
 
S-2.2 Full discussion of individual mutations 
S-2.1 Genes with mutations unique to moenomycin A resistant strains 
PurR 
The mutation I154fs in the Pur operon repressor protein was consistently present in all 6 evolved 
strains (MoeA 1-6). It was identified as a frame shift mutation, resulting in a truncated purR 
repressor protein. The truncation results in loss of the PRPP, 5-phosphoribosyl 1-pyrophosphate 
binding site. A deletion in this binding region has been shown to abolish repression of transcription 
of the Pur operon (1).  The Pur operon encodes genes involved in purine synthesis, specifically 
inosine monophosphate, a precursor compound related to AMP2 and DNA production. This 
mutation is consistent with other PurR mutations which have been previously implicated in 




A suite of point mutations were discovered in penicillin-binding protein 2 (pbp20 (D71V, Y196H and 
P234Q). These were all present in all 6 evolved strains except for strain 5 which lacked the D71V 
mutation.  Pbp2 catalyses the formation of the carbohydrate linkage in peptidoglycan and the 
glycosyltransferase domain is inhibited by moenomycin A (12).  When mapped onto the PBP2 
structure (2OLU5) the D71V mutation was found to be remote from the active site (S-figure 4 panel 
B, green) is likely that this mutation disrupts the hydrogen bonding made between Asp 71 and His 
94. It is likely that the D71V mutation results in a conformational change with possible implication on 
substrate binding.  The Y196H and P234Q mutations were found to be within the substrate binding 
pocket of the enzyme and be within bonding distance of moenomycin A (S-figure 4 panels C and D, 
cyan and magenta). These mutations are consistent with the findings of Rebets et al (13), who used 
phage mediated mutagenesis to induce moenomycin A resistance. There two of the same locations 
with mutations were reported, but with a differing residue at position 196 (Y>D as opposed to this 
study that obtained Y>H. The P234Q was the same in both studies. Rebets et al showed a 5-fold 
increase in the minimum inhibitory concentrations (MICs), from 0.5 μg mL−1 to 12.5 μg mL−1. Much 
higher rates of resistance were observed in this study in strains harbouring all six mutation from 




   
S-figure 4 The location and bonding interactions of residue within PBP2 that when mutated give rise to moenomycin A 
resistance. Panel A. The locations for the resistance mutations in PBP2, D71V (green), Y196H (cyan) and P234Q (magenta) 
in relation to Moenomycin A (red ball and stick) the surface of PBP2 shown in wheat.  (PDB code 2OLU (14)) 98%(91%) by 
BLAST. Panel B. PBP2 showing secondary structure in cartoon, the hydrogen bonding interaction between Asp71 (green) 
and His94 (yellow). It is likely be abolished by the D71V mutation. Panel C. PBP2 showing secondary structure in cartoon, 
the electrostatic interaction between OH group of Tyr196 (cyan) and the CCM/1000 atom of (red ball and stick) is likely to 
be abolished by the Y196H mutation. Panel D. PBP2 showing secondary structure in cartoon, the hydrogen bonding 
interaction between the nitrogen of Pro234 (magenta) and OCG /1000 atom of Moenomycin A. It is likely the bonding will 
be abolished by the P234Q mutation. The figure was drawn using PYMOL and  (PDB code :2OLU (14)) which show a high 
sequence identity to the Mutant PBP2 evolved in this study (98% (91% coverage) by BLAST 
https://blast.ncbi.nlm.nih.gov/Blast.cgi), all distances are shown in angstrom (dashed yellow lines). 
 
SagB 
The bifunctional autolysin SagB is a family 73 (http://www.cazy.org/GH73.html) muramidases which 
modulates peptidoglycan by the hydrolyses β-1,4-glycosidic linkage between N-acetylglucosaminyl 
(NAG) and N-acetylmuramyl (NAM) moieties during cell grown and division.  SagB shares a 37% 
identity (67% coverage) with another staphylococcal autolysin S. aureus autolysin E (atlE) (15) , in 
addition mutations in SagB have been show to effect the thickness of cell wall peptidoglycan in  S. 
aureus (16).  The N-terminal portion consists of a transmembrane helix and the catalytic domain is 
predicted to be outside the cell membrane TMHMM (http://www.cbs.dtu.dk/services/TMHMM/). 





F134L mutation lies within the Α-6 helix part of the L-domain.  It is unclear how the F134L mutation 
may confers moenomycin A resistance, however it is tempting to speculate that F134 may mediate a 
hitherto undescribed interaction.  
 
LyrA 
Two of the moenomycin A resistant strains (strains 3 and 4) have acquired a S107I mutation in the 
Lysostaphin resistance protein A hypothetical protein (lyrA). Lysostaphin endopeptidase which cuts 
the Gly-Gly bond of peptidoglycan of certain Staphylococci.  LyrA is a  intramembrane 
metalloprotease which has been shown to confer resistance to  Lysostaphin (17). It is unclear how 
alteration would lead to moenomycin A resistance, with little known about this enzyme, including 
the lack of solved protein structure.   
S-2.2 Genes with mutations unique to arg10-teixobactin resistant strains 
 
MprF Phosphatidylglycerol lysyltransferase 
The L826I mutation was found to be present in a Phosphatidylglycerol lysyltransferase Lys-tRNALys–
dependent lysyl-phosphatidylglycerol synthase (L-PGS) in arg10-teixobactin resistant strains 1,2,3 and 
4. This is an enzyme involved in Lipid homeostasis and has been shown to modify the polar head 
group of phosphatidylglycerol into the respective aminoacyl-ester of phosphatidylglycerol.  Its 
activity has been previously identified as a widely used strategy to mediate bacterial resistance(18), 
with this same mutation associated with daptomycin resistance (2). This enables bacteria to tolerate 
cationic peptides that are harmful to the integrity of the cell membrane and have been associated 
with resistance to a number of cationic cationic antimicrobial peptides (2). L-PGS consists of an N-
terminal transmembrane flippase domain and a C-terminal catalytic domain. Pfam, Blast and Clustal 
Omega alignment (https://www.ebi.ac.uk/Tools/msa/clustalo/) revealed a high degree of homology 
to the C-terminal catalytic domain and the deposited structure derived from B.licheniformis (2) (47% 
identify by blast). Analysis of this structure 4V36 pdf showed that the corresponding residue in B. 
licheniformis sequence (L844), was situated away from the ligand binding site in an helix near to the 
C-terminal end of the protein. It is unclear what effect and the L826I mutation might have on the 
activity of the enzyme, but it is possible that an alteration to the polar head group 
phosphatidylglycerol, may make the membrane less permeable to arg10-teixobactin and so provide a 
degree of resistance, by exclusion from its target.  
Icd 
Arg10-teixobactin strain 6 contains an A317P mutation in isocitrate dehydrogenase, this enzyme that 
catalyses the oxidative decarboxylation of isocitrate to yield α-ketoglutarate and CO2 with 
concomitant reduction of NADP+ to NADPH Icd (18)plays a critical role the TCA cycle. The mechanism 
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through which this may convey resistance to cell wall antimicrobials is unclear, and it may simply be 
that this is simply to offset the fitness costs of resistance. 
SrrA 
A G228E mis-sense mutation in the srrA regulatory repressor protein. Mutations were found to be 
present in arg10-teixobactin resistant strains 1,2,3 and 4. SrrAB belongs to the OmpR/PhoB family of 
repressor proteins. The role of srrA/B has been attributed to the regulation of energy transduction in 
response to changes in oxygen availability and has been linked to virulence alterations under 
microaerobic conditions (19). Pfam, Blast and clustal omega alignment 
(https://www.ebi.ac.uk/Tools/msa/clustalo/) revealed a degree of homology to the C-terminal 
catalytic domain of the deposited structure derived from Mycobacterium tuberculosis, REGX3 with a 
38% identity and 96% coverage (PDB code 20QR(20)). This mutation is found within a conserved GYK 
motif close to the C-terminal effector domain, which is usually involved in DNA-binding (20). 
KdpE 
A K187N miss-sense mutation in the Kdp transcriptional regulatory protein kdpE was found to be 
present in arg10-teixobactin resistant strains 1,2,3 and 4. This forms part of the two-component 
system (TCS) kdpD/kdpE, extensively studied for its regulatory role in potassium (K+) transport, has 
more recently been identified as an adaptive regulator involved in the virulence and intracellular 
survival of pathogenic bacteria.  KdpE regulates many downstream genes including virulence factors 
by directly binding to their promotor(21). Pfam, Blast and clustal omega alignment 
(https://www.ebi.ac.uk/Tools/msa/clustalo/) revealed a degree of homology (40% and 96% 
coverage) to KdpEB domain of the E.coli KdpE protein (PDB code 4KNY(21)), a member of the 
OmpR/PhoB family (22).   The mutation occurs in a none conserved region of the KdpEB domain, just 
outside the highly conserved DNA binding region. It appears to be situated such that it may in-part 
alter the coordination of a binding helix (E189 to R102 (4KNY numbering)) which interacts with one 
of the major grooves of DNA. Thus, this may affect DNA binding and regulation of the gene, changing 
the expression profiles of downstream virulence factors. Though the role that this has in 
antimicrobial resistance is unclear, it may have implications in a clinical setting. 
FtsW  
FtsW is a is a core member of the divisome complex and is essential for septal wall assembly cell wall 
separation(7, 23, 24).  FtsW is a peptidoglycan polymerase that is functional only in complex with its 
cognate penicillin-binding protein (7) .  It has been shown that FtsW interacts with PBP1b and lipid II. 
That PBP1b, ftsW and PBP3 co-purify suggests that they form a trimeric complex.  We have 
identified a mutation within ftsW in one of the 6 parallel arg10-teixobactin evolved stains (strain 6). 
Using sequence alignments and the analogous rodA structure of Thermus thermos (pdb code BAR_6) 
(25)We can predict the A260Q mutation lies in a highly conserved extracytoplasmic region, falling 
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between trans-membrane helix 7 and trans membrane helix 8.  Teixobactin has been shown to be a 
potent lipid II and lipid III binder (25). As such we speculate that lipid II, when bound to teixobactin, 
may interfere with the formation of the divisome complex. Further, that the mutation may lead to 
the exclusion of the ‘lipid II-teixobactin’ complex.  
GyrA 
DNA gyrase (Type IIA topoisomerase) is a DNA modulating enzyme that cuts both strands of the DNA 
helix simultaneously in order to manage DNA tangles and supercoils (26). The synonymous R655R 
mutation was present in trains arg10-teixobactin resistant strains 1, 2, 3 and 4. This codon usage 
went from 3.1% to 4.8% indicating a possible up regulation in the expression of this DNA replication 
regulation enzyme(27). 
PrmC 
Arg10-teixobactin strains 1, 2 and 4. Truncation of the protein due to the inclusion of a stop codon 
Q105stop. (n5)-glutamine Methyltransferase Protein glutamine Posttranslational methylation of 
release factors on the glutamine residue of a conserved GGQ motif is required for efficient 
termination of protein synthesis methylation at GGQ sites of protein chain release factors plays a 
pivotal role in the termination of translation(28). This mutation only allows the expression of the N-
terminal putative substrate binding domain. 
DltD 
Teichoic acids are bacterial cell wall compounds which are important for growth, biofilm formation, 
adhesion and virulence of S. aureus. DltD is an D-alanyl-lipoteichoic acid synthetase which anchors 
outside of the cell wall (5) (see Error! Reference source not found. panel e).  It catalyses the final 
transfer of the d-alanine to lipoteichoic acid. Interestingly strains of S. aureus which lack this d-
alanine decoration show an increased susceptibility to cationic antimicrobial peptides (5). It had 
been proposed that the reduced D-alanyl content of the cell wall results in an overall increase in 
negative cell surface charge, thus promoting attraction of the cationic antimicrobial peptides (29) . 
Pfam, Blast and clustal omega alignment (https://www.ebi.ac.uk/Tools/msa/clustalo/) revealed that the dltD 
sequence showed a 25% identity (80% identity) to the D-alanyl-lipoteichoic acid synthetase from 
Streptococcus pneumoniae R6 (PDB code D3BM).  According to mapping onto this structure the 
Q129P mutation, found in arg10-teixobactin resistant strains 1 and 2, is likely to be located on the 




S-3 Cross resistance of arg10-teixobactin resistant strains to teixobactin 
analogues 
Cell Line 1 2 3 4 5 6 Ancestor 
Orn10 teixobactin 1 1 2 2 4 4 1 
Cha10 teixobactin 1 2 2 2 2 2 0.5 
Chg10 teixobactin 2 1 2 1 2 1 1 
Ala10 teixobactin 1 1 1 2 2 2 1 
Leu10 teixobactin 0.5 1 0.5 0.5 0.5 1 0.25 
Val10 teixobactin 0.5 1 0.5 0.5 0.5 1 0.25 
Ile10 teixobactin 0.5 0.5 0.5 0.5 0.5 0.5 0.25 
Dap10 teixobactin 1 1 1 1 1 2 0.5 
D-Arg9-Ile10 teixobactin 0.5 0.5 1 1 1 1 0.5 
Arg9-Arg10 teixobactin 0.25 0.5 0.5 0.5 0.5 0.5 0.25 
D-Arg4-Arg10 teixobactin 0.5 1 0.5 1 0.5 1 0.5 
D-Arg4-Arg9-Arg10 
teixobactin 
0.5 0.5 1 0.5 0.5 0.5 0.5 
        
Average 0.77 0.92 1.04 1.04 1.25 1.38 0.54 
Arg10-teixobactin 8 8 4 5.3 5.3 8 2 
 
S-Table 3 A heat map showing the susceptibility of peak arg10-teixobactin (day 45) resistant strains susceptibility against a 
panel of teixobactin analogues. Heat mapping was applied independently by teixobactin analogue, comparing the six 
resistant strains and ancestral strain. Red colouring highlights the lowest MIC, moving to yellow then to green for the 
highest MICs. All analogues with the same structure as arg10-teixobactin except where stated modifications. Orn: Ornithine, 
Cha: Cyclohexylalanine, Chg: Cyclohexylglycine, Ala: Alanine, Leu: Leucine, Val: Valine, Ile, Isoleucine, Dap: Diaminopimelic 
acid, Arg: Arginine. 
 
 
S-figure 5 The correlation between the susceptibility of each strain against arg10-teixobactin, plotted against that same 
strains average susceptibility across the panel of screened teixobactin analogues (S-Table 3). The R-squared value was then 
plotted across the best fitting trendline and is displayed on the graph. 
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S-4 Changes in arg10-teixobactin minimum bactericidal concentration 
 
S-figure 6 Changes in the minimum bactericidal concentration of arg10-teixobactin against MRSA 33591 before (mean MBC 
8.0 µg /lL SEM 0) 0 and after (mean MBC 26.6 µg /lL SEM 3.4 ) induction of resistance. N=3, error bar indicates SEM. 
 
S-table 4 Physiological tests used selective to confirm the identity of 45 day evolved and ancestral S. aureus MRSA. E. 

















 X X   
Moenomycin A X 6 
replicates 
 X X   
Rifampicin X 6 
replicates 
 X X   
Control selection 
free X 6 replicates 
 X X   
E. faecium DSM 
17050 
X X X X X 
S. epidermis DSMZ 
28319 
X X X X  
K. pneumoniae 
ATCC 700603 







S-5 Mutation profiles of resistance 
 
S-table 5 The mutation profile of arg10-teixobactin resistant cells, showing the distribution of mutations across mutations that appear to correlate with ‘key’ mutations conveying resistance. 




































































































































































































































































































































































Ancestor 2 WT WT WT WT WT WT WT WT WT WT 
1 8       X X X X 
2 8       X X X X 
3 4     X X X X X X 
4 5.3      X X X X X 
5 5.3 X X X X X X X X   







S-table 6 The mutation profile of moenomycin A resistant cells, showing the distribution of mutations across mutations that appear to correlate with ‘key’ mutations conveying resistance. Ticks 
represent the presence of the mutations, crosses the absence of change from the wild-type. 
 Target protein / SNP 
Strain 
Resistance after 

















Ancestor 0.125      
1 >128      
2 >128      
3 >128      
4 >128      
5 >128  X    







S-6.1 All mutations arising in arg10-teixobactin resistant S. aureus strains 
 
S-table 7 A list of all detected polymorphisms across all six replicate strains with evolved resistance to arg10-teixobactin. 
Product Gene Location Reference Alternate SNP effect SNP shortened Strains 
Phosphatidylglyce-rol 
lysyltransferase 
mprF 01285 C A missense_variant c.2476C>A p.Leu826Ile SNP Leu826Ile 1, 2, 3, 4 
SrrA regulatory repressor 
protein 




kdpE 02037 C A missense_variant c.561G>T p.Lys187Asn SNP Lys187Asn 1, 2, 3, 4 
DNA gyrase A gyrA 02622 C A synonymous_variant c.1965C>A p.Arg655Arg syn Arg655Arg 1, 2, 3, 4 
Glutamine 
Methyltransferase 
prmC 02001 C T stop_gained c.313C>T p.Gln105* stop codon Gln105* 1, 2, 4 
Protein dltD dltD 00857 A C missense_variant c.386A>C p.Gln129Pro SNP Gln129Pro 1, 2 
hypothetical protein  01693 G A synonymous_variant c.762G>A p.Pro254Pro syn Pro254Pro 1, 2, 4 
hypothetical protein  01693 A G missense_variant c.106A>G p.Asn36Asp SNP Asn36Asp 1,4  
hypothetical protein  01693 G T missense_variant c.524G>T p.Arg175Ile SNP Arg175Ile 1, 4 
hypothetical protein  01693 A ACTGAT frameshift_variant c.633_637dupTGATC p.His213fs frameshiftHis213fs 1, 4 
hypothetical protein  01693 T A synonymous_variant c.777T>A p.Thr259Thr syn Thr259Thr 1, 4 
hypothetical protein  01693 T C synonymous_variant c.783T>C p.Ile261Ile syn Ile261Ile 1, 4 
hypothetical protein  01693 T A missense_variant c.139T>A p.Phe47Ile SNP Phe47Ile 2, 6 
hypothetical protein  01693 T C synonymous_variant c.186T>C p.Ile62Ile syn Ile62Ile 2, 6 











inframe_del Asn76_Asp82del 2, 6 
hypothetical protein  01693 A G synonymous_variant c.276A>G p.Arg92Arg syn Arg92Arg 2, 6 
hypothetical protein  01693 A G missense_variant c.461A>G p.Asp154Gly SNP Asp154Gly 2, 6 
hypothetical protein  01693 TGTG AGTA missense_variant c.490_493delTGTGinsAGTA 
p.CysAla164SerThr 
SNP CysAla164SerThr 2, 6 
hypothetical protein  01693 AGAACTG GAACTA frameshift_variant&missense_variant 
c.523_529delAGAACTGinsGAACTA p.Arg175fs 
frameshift& snpArg175fs 2, 6 
hypothetical protein  01693 G T missense_variant c.549G>T p.Lys183Asn SNP Lys183Asn 2, 6 
hypothetical protein  01693 T C synonymous_variant c.621T>C p.Ser207Ser syn Ser207Ser 2, 6 
hypothetical protein  01693 G A synonymous_variant c.762G>A p.Pro254Pro syn Pro254Pro 2, 6 
hypothetical protein  01694 A G missense_variant c.86A>G p.Asp29Gly SNP Asp29Gly 1 
hypothetical protein  01694 G A missense_variant c.127G>A p.Asp43Asn SNP Asp43Asn 1 
hypothetical protein  01694 C T synonymous_variant c.228C>T p.Cys76Cys syn Cys76Cys 1 
hypothetical protein  01694 G T missense_variant c.241G>T p.Ala81Ser SNP Ala81Ser 1 
hypothetical protein  01694 GCAA ACAT missense_variant c.255_258delGCAAinsACAT 
p.Gln86His 
SNP Gln86His 1 
hypothetical protein  01694 A G synonymous_variant c.279A>G p.Ser93Ser syn Ser93Ser 1 
hypothetical protein  01694 A G missense_variant c.86A>G p.Asp29Gly SNP Asp29Gly 6 




hypothetical protein  01694 C T synonymous_variant c.228C>T p.Cys76Cys syn Cys76Cys 6 
hypothetical protein  01694 G T missense_variant c.241G>T p.Ala81Ser NP Ala81Ser 6 
hypothetical protein  01694 GCAA ACAT missense_variant c.255_258delGCAAinsACAT 
p.Gln86His 
SNP Gln86His 6 
hypothetical protein  01694 A G synonymous_variant c.279A>G p.Ser93Ser syn Ser93Ser 6 
cell wall-anchored 
adhesion  (Serine-
aspartate repeat)  
sdrD 00547 C T synonymous_variant c.3651C>T p.Asp1217Asp syn Asp1217Asp 4 
cell wall-anchored 
adhesion  (Serine-
aspartate repeat)  
sdrD 00547 A G synonymous_variant c.3672A>G p.Ser1224Ser syn Ser1224Ser 4 
cell wall-anchored 
adhesion  (Serine-
aspartate repeat)  
sdrD 00547 C T synonymous_variant c.3732C>T p.Ser1244Ser syn Ser1244Ser 4 
cell wall-anchored 
adhesion  (Serine-
aspartate repeat)  
sdrD 00547 G A synonymous_variant c.3738G>A p.Ser1246Ser syn Ser1246Ser 4 
cell wall-anchored 
adhesion  (Serine-
aspartate repeat)  
sdrD 00547 TAGTGAT CAGCGAC synonymous_variant 
c.3765_3771delTAGTGATinsCAGCGAC p.1258 
syn TAGTGATinsCAGCGAC 4 
cell wall-anchored 
adhesion  (Serine-
aspartate repeat)  
sdrD 00547 T C synonymous_variant c.3783T>C p.Asp1261Asp syn Asp1261Asp 4 
cell wall-anchored 
adhesion  (Serine-
aspartate repeat)  
sdrE 00548 C T synonymous_variant c.2895C>T p.Asp965Asp syn Asp965Asp 6 
cell wall-anchored 
adhesion  (Serine-
aspartate repeat)  
sdrE 00548 C T synonymous_variant c.2901C>T p.Asp967Asp syn Asp967Asp 6 
cell wall-anchored 
adhesins, 






sdrE 00548 G A synonymous_variant c.2928G>A p.Ser976Ser syn Ser976Ser 6 
cell wall-anchored 
adhesins, 
sdrE 00548 T C synonymous_variant c.2967T>C p.Asp989Asp syn Asp989Asp 6 
cell wall-anchored 
adhesins, 
sdrE 00548 CGAC TGAT synonymous_variant c.3060_3063delCGACinsTGAT 
p.1022 
syn del CGACinsTGAT 6 
cell wall-anchored 
adhesins, 
sdrE 00548 G A synonymous_variant c.3084G>A p.Ser1028Ser syn Ser1028Ser 6 
cell wall-anchored 
adhesins, 
clfA 00782 C T synonymous_variant c.2280C>T p.Asp760Asp syn Asp760Asp 6 
Putative peptidoglycan 
glycosyltransferase 
ftsW 01033 G A missense_variant c.778G>A p.Ala260Thr SNP Ala260Thr 6 
Extracellular matrix-
binding protein 
ebh_1 01359 A T missense_variant c.20006T>A p.Val6669Glu SNP Val6669Glu 6 






A missense_variant c.235G>A p.Asp79Asn 
SNP Asp79Asn 5 
hypothetical protein  106990 
A 
G missense_variant c.106A>G p.Asn36Asp 
SNP Asn36Asp 5 
hypothetical protein  107408 
G 
T missense_variant c.524G>T p.Arg175Ile 
SNP Arg175Ile 5 
hypothetical protein  107515 
A 
ACTGAT frameshift_variant c.633_637dupTGATC p.His213fs 
frameshift 5 
Protoporphyrinogen 
oxidase hemY 29534 
T 
C start_lost c.2T>C p.Val1 
Loss of start codon 5 















S-6.2 All mutations arising in moenomycin A resistant S. aureus strains 
 
S-table 8 A list of all detected polymorphisms across all six replicate strains with evolved resistance to moenomycin A 
Product Gene Location Reference Alternate SNP effect SNP shortened Strains 
Pur operon repressor purR 00438 AT A frameshift_variant c.460delA p.Ile154fs Del Ile154fs 1, 2, 3, 4, 
5, 6 












ponA 01374 C A missense_variant c.701C>A p.Pro234Gln SNP Pro234Gln 1, 2, 3, 4, 
5, 6 
Bifunctional autolysin atl_2 01671 A G missense_variant c.400T>C p.Phe134Leu SNP Phe134Leu 1, 2, 3, 4, 
5, 6 
hypothetical protein  01693 T A missense_variant c.139T>A p.Phe47Ile SNP Phe47Ile 1, 2, 5, 6 
hypothetical protein  01693 T C synonymous_variant c.186T>C p.Ile62Ile Syn Ile62Ile 1, 2, 5, 6 
hypothetical protein  01693 C T synonymous_variant c.192C>T p.Phe64Phe Syn Phe64Phe 1, 2, 5, 6 






Inframe del Asp82del 1, 2, 5, 6 
hypothetical protein  01693 A G synonymous_variant c.276A>G p.Arg92Arg Syn Arg92Arg 1, 2, 5, 6 
hypothetical protein  01693 A G missense_variant c.461A>G p.Asp154Gly SNP Asp154Gly 1, 2, 5 
hypothetical protein  01693 TGTG AGTA missense_variant c.490_493delTGTGinsAGTA 
p.CysAla164SerThr 




hypothetical protein  01693 AGAACTG GAACTA frameshift_variant&missense_variant 
c.523_529delAGAACTGinsGAACTA p.Arg175fs 
Frameshift/SNP Arg175fs 1, 2, 5 
hypothetical protein  01693 G T missense_variant c.549G>T p.Lys183Asn SNP Lys183Asn 1, 2, 5 
hypothetical protein  01693 T C synonymous_variant c.621T>C p.Ser207Ser Syn Ser207Ser 1, 2, 5 
hypothetical protein  01693 G A synonymous_variant c.762G>A p.Pro254Pro Syn Pro254Pro 1, 2, 5 
hypothetical protein  01694 C T synonymous_variant c.228C>T p.Cys76Cys Syn Csy76Cys 1, 2 
hypothetical protein  01694 G T missense_variant c.241G>T p.Ala81Ser SNP Ala91Ser 1, 2 
hypothetical protein  01694 GCAA ACAT missense_variant c.255_258delGCAAinsACAT 
p.Gln86His 
SNP Gln86His 1, 2 
hypothetical protein  01694 A G synonymous_variant c.279A>G p.Ser93Ser Syn Ser93Ser 1, 2 
Lysostaphin resistance 
protein A 
LyrA 02220 G T missense_variant c.320G>T p.Ser107Ile SNP Ser107Ile 3, 4 
hypothetical protein  00702 G A missense_variant c.143T>G p.Ile48Ser Ile48Ser 5 
hypothetical protein  01682 C T missense_variant c.434G>A p.Ser145Asn SNP Ser145Asn 2 
Stress response protein 
NhaX 
nhaX 01614 A T missense_variant c.10A>T p.Asn4Tyr Asn4Tyr 5 
hypothetical protein  01671 C T missense_variant c.434G>A p.Ser145Asn Ser145Asn 4 
hypothetical protein  01716 A G synonymous_variant c.861T>C p.Ile287Ile Ile287Ile 5 
hypothetical protein  01693 T C synonymous_variant c.783T>C p.Ile261Ile Syn Ile261Ile 2 







G frameshift_variant c.564_573delCAATGCAAGT 
p.Asn189fs 




Clumping factor B  02529 ATCT GTCC synonymous_variant c.1908_1911delAGATinsGGAC 
p.638 
Syn AGAT > GGAC 5 
Clumping factor B  02529 A G synonymous_variant c.1902T>C p.Ser634Ser Syn Ser634Ser 5 
Protein McrC mcrC 00021 T A missense_variant c.1013T>A p.Ile338Lys Syn Ile338Lys 5 
hypothetical protein  00469 C G synonymous_variant c.51G>C p.Ala17Ala Syn Ala17Ala 6 
Serine-aspartate repeat-
containing protein I 
sdrI 00546 G A synonymous_variant c.2310G>A p.Ser770Ser Syn Ser770Ser 5 
Serine-aspartate repeat-
containing protein I 
sdrI 00546 A G synonymous_variant c.2328A>G p.Ser776Ser Syn Ser776Ser 5 
Serine-aspartate repeat-
containing protein I 
sdrI 00546 T C synonymous_variant c.2349T>C p.Asp783Asp Ser Asp783Asp 5 
Serine-aspartate repeat-
containing protein I 
sdrI 00546 C T synonymous_variant c.2421C>T p.Asp807Asp Syn Asp807Asp 5 
Serine-aspartate repeat-
containing protein I 
sdrI 00546 T C synonymous_variant c.2448T>C p.Ser816Ser Syn Ser816Ser 5 
Serine-aspartate repeat-
containing protein I 
sdrI 00546 TTCAGAC CTCGGAT synonymous_variant 
c.2457_2463delTTCAGACinsCTCGGAT p.822 
Syn TTCAGAC > CTCGGAT 5 
Serine-aspartate repeat-
containing protein I 
sdrI 00546 C T synonymous_variant c.2493C>T p.Asp831Asp Syn Asp831Asp 5 
Serine-aspartate repeat-
containing protein D 
sdrD 00547 TTCAGAC CTCTGAT synonymous_variant 
c.3561_3567delTTCAGACinsCTCTGAT p.1190 
Syn TTCAGAC > CTCTGAT 5 
Serine-aspartate repeat-
containing protein E 
sdrE 00548 C T synonymous_variant c.3171C>T p.Asp1057Asp Syn Asp1057Asp 5 
Serine-aspartate repeat-
containing protein E 
sdrE 00548 C T synonymous_variant c.3177C>T p.Asp1059Asp Syn Asp1059Asp 5 
Serine-aspartate repeat-











containing protein E 
sdrE 00548 CAGCGAC TAGTGAT synonymous_variant 
c.3201_3207delCAGCGACinsTAGTGAT p.1070 
Syn CAGCGAC > TAGTGAT 5 
Serine-aspartate repeat-
containing protein E 
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